Search research articles
Contact Us
Filters
Showing results (101-110 of 176) with videos related to
Page
of 18
Sort By:
Leukemia & Lymphoma
|
October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini, Preetesh Jain, Long Trinh, et al.
American Journal of Hematology
|
April 3, 2021
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
Hans C Lee, Lei Feng, Onyeka Oriabure, et al.
Blood
|
April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
Leukemia & Lymphoma
|
July 7, 2024
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center
Jared R Zhang, Susan Y Wu, Preetesh Jain, et al.
British Journal of Haematology
|
June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
Dai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia & Lymphoma
|
August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
British Journal of Haematology
|
November 5, 2020
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy
Preetesh Jain, Loretta Nastoupil, Jason Westin, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Cancer
|
August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
Koichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer
|
October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 176) with videos related to
Sort By:
Page
of 18
Leukemia & Lymphoma
|
October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini, Preetesh Jain, Long Trinh, et al.
American Journal of Hematology
|
April 3, 2021
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
Hans C Lee, Lei Feng, Onyeka Oriabure, et al.
Blood
|
April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
Leukemia & Lymphoma
|
July 7, 2024
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center
Jared R Zhang, Susan Y Wu, Preetesh Jain, et al.
British Journal of Haematology
|
June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
Dai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia & Lymphoma
|
August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
British Journal of Haematology
|
November 5, 2020
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy
Preetesh Jain, Loretta Nastoupil, Jason Westin, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Cancer
|
August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
Koichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer
|
October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
Page
of 18